Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Minerva Gastroenterology 2021 September;67(3) > Minerva Gastroenterology 2021 September;67(3):254-63

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW  IMPACT OF DIRECT ANTIVIRAL AGENTS (DAAS) ON EXTRAHEPATIC DISEASES IN PATIENTS WITH CHRONIC HEPATITIS C 

Minerva Gastroenterology 2021 September;67(3):254-63

DOI: 10.23736/S2724-5985.21.02875-8

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C

Grazia PENNISI 1 , Federica SPATOLA 1, Lorenza DI MARCO 2, Vincenzo DI MARTINO 1, Vito DI MARCO 1

1 Section of Gastroenterology and Hepatology, Department of Health Promotion, Maternal Child, Internal and Specialist Medicine, University of Palermo, Palermo, Italy; 2 Unit of Gastroenterology, Department of Medical Specialties, University of Modena and Reggio Emilia, Modena, Italy



INTRODUCTION: In the last years the Hepatitis C virus (HCV) infection was a relevant public health problem due to the large number of affected people worldwide and the impact on hepatic and extrahepatic complications. The availability of direct-acting antivirals (DAAs) and the very high rate of sustained virological response (SVR) after treatment has radically changed the course of HCV chronic infection.
EVIDENCE ACQUISITION: We searched PubMed for articles published between January 1, 1995, through December 31, 2020, in English language.
EVIDENCE SYNTHESIS: Robust evidence showed a close link between HCV infection and development of cardiovascular disease (CVD), as result of the atherogenic effect of the virus.
CONCLUSIONS: This review aimed to explore the evidence linking HCV infection with cardiovascular disease and to evaluate the impact of SVR after DAAs on cardiovascular complications.


KEY WORDS: Hepatitis C, chronic; Cardiovascular diseases; Antiviral agents

inizio pagina